NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Acne Therapeutics Market- Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 391484
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
痤瘡治療藥的全球市場:成長,趨勢,及預測(2019年∼2024年) Acne Therapeutics Market- Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 111 Pages



第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭情形

第5章 市場區隔

  • 各療法
    • 治療藥
    • 其他
  • 各給藥途徑
    • 口服
    • 局部
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Cipher Pharmaceuticals
    • Glaxosmithkline PLC
    • Bayer AG
    • Teva Pharmaceuticals
    • Ranbaxy
    • Allergan
    • F. Hoffmann-la Roche Ltd
    • Nestle SA (Galderma)
    • Johnson & Johnson
    • Valeant Pharmaceuticals International Inc.

第7章 市場機會及今後趨勢


Product Code: 51177

The key factors propelling the growth of the acne therapeutics market are increasing sedentary lifestyles and unhealthy lifestyles, the rise in disposable income of consumers, increasing awareness about upcoming trends in acne treatments, and high prevalence of acne, globally.

  • The diet and nutrient intake determine the overall health of an individual. The food that is high in refined carbohydrates increases insulin, which results in hormonal problems, promoting acne formation.
  • More than 90% of the world's population is found to be affected by acne at some point in their life. In the United States, there are 60 million people suffering from acne problems. This includes all grades of acne, from the mild, occasional breakout to more severe conditions. Of the 60 million, 20% have some form of acne bad enough that it results in scarring of the skin. Therefore, there is increasing adoption of acne therapeutics, which helps in driving the overall market.
  • In addition, rapid economic growth has also led to a substantial increase in the disposable incomes of middle-class people. With this increasing income, people are ready to spend more on their facial looks. Thus, the market for acne therapeutics is projected to grow rapidly over the forecast period.

Key Market Trends

Topical is the Segment Under Administration that is Expected to Grow the Fastest

The utilization rate of topical medications for acne treatment is high, owing to the high availability of these acne products, with a high success rate and lesser side effects. These agents are directly applied to the skin and need to be used continuously for longer periods of time, from several weeks to months, to get effective results. There are topical antibiotics, retinoids, and other products, like azelaic acid and benzoyl peroxides, which are available in the form of gels, lotions, and creams. ​

Retinoids have been used for more than 25 years in the treatment of acne vulgaris. In recent years, new polyaromatic retinoids have been developed for the topical treatment of acne​.

The most important topical antibiotics for acne treatment are tetracycline, erythromycin, and clindamycin. ​

Therefore, the preference for topical treatment is more, compared to the oral mode of therapeutic administration. These oral medications are recommended as systemic therapies after topical treatments fail to evoke a response.

Asia-Pacific Holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period

Asia-Pacific is expected to be the fastest-growing region, due to increasing sedentary lifestyles and unhealthy food habits. Prosperity and a faster pace of life have changed the Chinese eating habits. Eating too much with high amounts of fat and calories and exercising less have led to an increase in obesity and acne problems. However, Asia-Pacific is expected to register the highest CAGR, due to the increase in affordability, surge in healthcare expenditure, and rise in awareness about safe acne medication products.

Competitive Landscape

The acne therapeutics market is highly competitive and consists of several major players and local players in the market. In the coming years, few other players are expected to enter the market. Some of the few major players include Allergan PLC, Valeant Pharmaceutical International Inc., Bayer AG, and Galderma (Nestle Skin Health), Roche, Teva, and Sun Pharma.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Sedentary Lifestyle and Unhealthy Food Habits
    • 4.2.2 Increasing Awareness About Current and Upcoming Acne Treatments
    • 4.2.3 High Global Acne Prevalence
  • 4.3 Market Restraints
    • 4.3.1 Safety Issues Regarding the Products
    • 4.3.2 Entry of Generics in the Market
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Treatment
    • 5.1.1 Therapeutics
      • Retinoid
      • Antibiotics
      • Hormonal Agents
      • Anti-inflammatory
      • Other Agents
    • 5.1.2 Other Treatments
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Topical
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Cipher Pharmaceuticals
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Bayer AG
    • 6.1.4 Teva Pharmaceuticals
    • 6.1.5 Ranbaxy (Sun Pharmaceuticals)
    • 6.1.6 Allergan PLC
    • 6.1.7 F. Hoffmann-la Roche Ltd
    • 6.1.8 Nestle SA (Galderma)
    • 6.1.9 Johnson & Johnson
    • 6.1.10 Bausch Health Companies Inc.